VAP-1 (vascular inflammation)

Ongoing clinical trials and approved products targeting VAP-1 (vascular inflammation), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

2ongoing imaging trials

0approved products

Target note

Full name: Vascular adhesion protein 1 (VAP-1)
Nature: Endothelial adhesion molecule exposed during inflammation.
Normal expression: —
Value: Imaging vascular and joint inflammation.
Approaches: [68Ga]Siglec-9.
Indications explored: Rheumatoid arthritis, vasculitis, infections (research).
Points of caution: Early stage.

Ongoing imaging trials · 2Open in the radar →

Trial	Phase	Status	Sponsor	Countries
[68Ga]Ga-Siglec-9 (VAP-1)2024-519864-42-00 · Atherosclerosis and vessels	Phase 2	Not yet recruiting	Turku University Hospital	1
SIGLEC · [68Ga]Ga-Siglec-9 (VAP-1)NCT03755245 · Atherosclerosis and vessels	No phase	By invitation	Turku University Hospital	1

Cite this page

VAP-1 (vascular inflammation). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/vap-1-vascular-inflammation/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.